Literature DB >> 2156744

Effect of carbachol and cyclic GMP on susceptibility to ventricular fibrillation.

G E Billman1.   

Abstract

Reductions in cardiac vagal tone have been shown to correlate with increased susceptibility to ventricular fibrillation (VF). If these reductions in vagal tone contribute to VF, one would predict that interventions that increase vagal tone should protect against these lethal arrhythmias. Therefore, VF was induced in 17 mongrel dogs with healed myocardial infarctions by a 2-min coronary occlusion during exercise. On a subsequent day, the cholinergic agonist carbachol (20 micrograms/kg, i.v.) was given before the exercise plus ischemia test (n = 14). Carbachol elicited significant reductions in heart rate (control 204.5 +/- 27.7 vs. carbachol 147.0 +/- 49.6 beats/min) and prevented VF in 11 of 14 animals. When the decline in heart rate was prevented by ventricular pacing, carbachol prevented VF in five of six animals. Cyclic GMP may act as an intracellular messenger of cholinergic activation; therefore, 8-bromo cyclic GMP (n = 9) was infused (100-150 micrograms.kg-1.min-1, i.v.) throughout the exercise beginning 45 min before onset of exercise. Heart rate increased but VF was prevented in eight of nine animals. Similar results were noted for dibutyryl cyclic GMP (n = 5). These data suggest that cholinergic agonists and cyclic GMP can prevent VF in susceptible animals independently of heart rate changes.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2156744     DOI: 10.1096/fasebj.4.6.2156744

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  10 in total

1.  The local intracoronary administration of methylene blue prevents the pronounced antiarrhythmic effect of ischaemic preconditioning.

Authors:  A Vegh; J G Papp; L Szekeres; J Parratt
Journal:  Br J Pharmacol       Date:  1992-12       Impact factor: 8.739

Review 2.  The role of the autonomic nervous system in sudden cardiac death.

Authors:  Marmar Vaseghi; Kalyanam Shivkumar
Journal:  Prog Cardiovasc Dis       Date:  2008 May-Jun       Impact factor: 8.194

3.  Autonomic boundary conditions for ventricular fibrillation and their implications for a novel defibrillation technique.

Authors:  Isaac Naggar; Sae Uchida; Haroon Kamran; Jason Lazar; Mark Stewart
Journal:  J Physiol Sci       Date:  2012-08-15       Impact factor: 2.781

4.  Activation of cardiac muscarinic receptor and ischemic preconditioning effects in in situ rat heart.

Authors:  F Yamaguchi; Y Nasa; K Yabe; S Ohba; Y Hashizume; H Ohaku; K Furuhama; S Takeo
Journal:  Heart Vessels       Date:  1997       Impact factor: 2.037

5.  Effect of low doses of scopolamine on RR interval variability, baroreflex sensitivity, and exercise performance in patients with chronic heart failure.

Authors:  B Casadei; J Conway; C Forfar; P Sleight
Journal:  Heart       Date:  1996-03       Impact factor: 5.994

6.  Effects of zaprinast and rolipram on platelet aggregation and arrhythmias following myocardial ischaemia and reperfusion in anaesthetized rabbits.

Authors:  M Holbrook; S J Coker
Journal:  Br J Pharmacol       Date:  1991-08       Impact factor: 8.739

7.  Preconditioning of the ischaemic myocardium; involvement of the L-arginine nitric oxide pathway.

Authors:  A Vegh; L Szekeres; J Parratt
Journal:  Br J Pharmacol       Date:  1992-11       Impact factor: 8.739

8.  An endogenous protectant effect of cardiac cyclic GMP against reperfusion-induced ventricular fibrillation in the rat heart.

Authors:  R Pabla; P Bland-Ward; P K Moore; M J Curtis
Journal:  Br J Pharmacol       Date:  1995-12       Impact factor: 8.739

9.  Effect of a 'vagomimetic' atropine dose on canine cardiac vagal tone and susceptibility to sudden cardiac death.

Authors:  J R Halliwill; G E Billman; D L Eckberg
Journal:  Clin Auton Res       Date:  1998-06       Impact factor: 4.435

Review 10.  Abnormalities of autonomic nervous control in human hypertension.

Authors:  S Julius
Journal:  Cardiovasc Drugs Ther       Date:  1994-03       Impact factor: 3.727

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.